Content deleted Content added
m Reverted edit by MEDICINEGUIDES (talk) to last version by Facts707 |
Removed 2 display-authors attributes from cite entries that match that of "cs1 config" to exclude the article from Category:CS1 maint: overridden setting. Used lowercase "cite" template everywhere for consistency, as the majority of instances used lowercase already. |
||
Line 50:
<!-- Pharmacokinetic data -->
| bioavailability= 35–76%<ref>{{cite web | title=Prilosec- omeprazole magnesium capsule, delayed release Prilosec- omeprazole magnesium granule, delayed release | website=DailyMed | date=22 December 2016 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1b077e6-b070-43f2-a98e-380cc635419d | access-date=15 February 2020 | archive-date=27 December 2019 | archive-url=https://web.archive.org/web/20191227184048/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1b077e6-b070-43f2-a98e-380cc635419d | url-status=live }}</ref><ref>{{cite journal | vauthors = Vaz-da-Silva M, Loureiro AI, Nunes T, Maia J, Tavares S, Falcão A, Silveira P, Almeida L, Soares-da-Silva P
| protein_bound = 95%
| metabolism = [[Liver]] ([[CYP2C19]], [[CYP3A4]])
Line 116:
===Peptic ulcers===
Peptic ulcers may be treated with omeprazole. Infection with ''[[Helicobacter pylori]]'' can be treated by taking omeprazole, [[amoxicillin]], and [[clarithromycin]] together for 7–14 days.<ref>{{cite journal | vauthors = Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F | title = Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication | journal = Annals of Internal Medicine | volume = 147 | issue = 8 | pages = 553–562 | date = October 2007 | pmid = 17938394 | doi = 10.7326/0003-4819-147-8-200710160-00008 | s2cid = 11644009 }}</ref> Amoxicillin may be replaced with [[metronidazole]] in patients who are allergic to penicillin.<ref name="Maastricht_2_Consensus_Report">{{cite journal | vauthors = Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ
==Adverse effects==
Line 139:
There is a possible association between long term use and dementia which requires further study to confirm.<ref>{{cite journal | vauthors = Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, Bazzoli F | title = Proton pump inhibitors: Risks of long-term use | journal = Journal of Gastroenterology and Hepatology | volume = 32 | issue = 7 | pages = 1295–1302 | date = July 2017 | pmid = 28092694 | doi = 10.1111/jgh.13737 | doi-access = free }}</ref>
A review article in ''[[U.S. Pharmacist]]'' in 2013 states that long-term use of PPIs is associated with [[Hypocalcaemia|decreased calcium absorption]] (causing increased risk of [[osteoporosis]] and [[Bone fracture|fractures]]), [[Magnesium deficiency|decreased magnesium absorption]] (causing [[Electrolyte imbalance|electrolyte disturbances]]), and increased risk of certain infections such as ''[[C. difficile]]'' and [[community-acquired pneumonia]]. They hypothesize that this is due to decreased stomach acid production.<ref>{{
===Pregnancy and breastfeeding===
Line 193:
==History==
{{main|Discovery and development of proton pump inhibitors }}
Omeprazole was first made in 1979 by Swedish AB Hässle, part of [[Astra AB]]. It was the first of the proton pump inhibitors (PPI).<ref>{{
==Society and culture==
Line 203:
application of two different coatings to a drug in pill form to ensure, that the omeprazole did not disintegrate before reaching its intended site of action in stomach. Although the solution by means of two coating was obvious, the patent was found valid, because the source of the problem was non-obvious and was discovered by the patentee.<ref>{{cite web | url=https://scholar.google.com/scholar_case?case=12553883911671736992&q=+In+re+Omeprazole+Patent+Litigation&hl=en&as_sdt=40000003 | title=IN RE OMEPRAZOLE PATENT LITIGATION, Court of Appeals, Federal Circuit 2011 - Google Scholar }}</ref>
In September 2023, AstraZeneca announced it would pay $425 million to settle product liability litigations against Prilosec in the United States.<ref>{{
=== Brand names ===
| |||